Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
2 authors.
Linda M S ResarDepartments of Medicine (Hematology), Oncology, Pathology and Institute for Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-4004-7060
Li Z LuoDepartments of Medicine (Hematology), Oncology, Pathology and Institute for Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-8680-4119
Funding
Clonal Hematopoiesis in Healthy Individuals from Families with Early OnsetCoronary Artery DiseaseR01HL143818 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BECKER, LEWIS C, RESAR, LINDA M S · 2019 to 2022
$3.3M
HMGA Chromatin Remodeling Proteins in Tumor Progression in Myeloproliferative Neoplasms (MPN)R01HL145780 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI MOLITERNO, ALISON R, RESAR, LINDA M S · 2018 to 2021
$1.9M
The HMGA1 Chromatin Regulator in Hematopoietic Stem Cells with AgingR01DK102943 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI RESAR, LINDA M S · 2017 to 2019
$884k
Targeting HMGA1-Mediated Progression and Immune Evasion in Myeloproliferative DiseasesF31HL156608 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KIM, YOUNGEUN JOSEPH · 2021 to 2024
$147k
National Insititutes of Health, Maryland Stem Cell Fund, Alex's Lemonade Stand Foundation, RALLY Foundation, B+ Foundation, Children's Cancer Research Fund R01 CA232741, R01 HL145780, R01 DK102943, R01 HL143818NHLBI NIH HHS F31 HL156608NHLBI NIH HHS R01 HL143818NHLBI NIH HHS R01 HL145780NIDDK NIH HHS R01 DK102943
6 · The paper itself
Abstract
Patients with chronic, indolent myeloproliferative neoplasms (MPNs) are at risk for transformation to highly lethal leukemia, although targetable mechanisms driving progression remain elusive. We discovered that the
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
High Mobility Group A1 Chromatin Keys: Unlocking the Genome During MPN Progression. · full record | OpenQuestion